Aptevo Therapeutics Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Aptevo reported Q3 2026 results showing mipletamig achieved 79% CR/CRi remission rate in 14 evaluable TP53-mutated AML patients (vs. 41% historical benchmark), with 10 of 47 patients advancing to stem cell transplantation. In August 2026, the company raised $4.5M gross ($4.1M net) through warrant exercises (254,922 shares at $4.03) and private placement (861,708 shares/pre-funded warrants at $4.03), plus new warrants covering 5.6M shares at $4.03. Cash position declined to $8.3M (Sept 30) from $9.8M (June 30); Q3 net loss was $6.5M.
Why this rating
Clinical efficacy data materially strengthens lead candidate; $4.5M capital raise is 46% of market cap, extending runway. Event is significant relative to $9.8M company size, though cash burn remains substantial risk.
Tradability signal
NO TRADE
No trade: only ~$26k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.63 ▲ 4.08% | at our read · unknown $0.61 | +10 min · unknown $0.60 ▼ 1.52% | +30 min · unknown $0.60 ▼ 0.91% | +1 hr · unknown $0.56 ▼ 7.47% | +4 hrs · unknown $0.55 ▼ 9.78% |
The stock had already moved -3.92% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.